Furthermore, it was found that COSM reduced LPS translocation due to intestinal flora, improved the expression of intestinal barrier function-related proteins, and ultimately reduced the expression level of the liver LPS/TLR4/NF-κB signaling pathway, thereby improving liver disease in NAFLD mice. This evidence concerns the gene NFKB1 and liver disorder.